Literature DB >> 24687823

Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go?

David H Johnson1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24687823     DOI： 10.1200/JCO.2014.55.1929

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Authors:  Courtney Davis
Journal:  Soc Sci Med       Date:  2014-12-02       Impact factor: 4.634

2.  Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma.

Authors:  A Po; M Silvano; E Miele; C Capalbo; A Eramo; V Salvati; M Todaro; Z M Besharat; G Catanzaro; D Cucchi; S Coni; L Di Marcotullio; G Canettieri; A Vacca; G Stassi; E De Smaele; M Tartaglia; I Screpanti; R De Maria; E Ferretti
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

3.  Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.

Authors:  Narasimha Kumar Karanam; Kalayarasan Srinivasan; Lianghao Ding; Brock Sishc; Debabrata Saha; Michael D Story
Journal:  Cell Death Dis       Date:  2017-03-30       Impact factor: 8.469
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.